Zobrazeno 1 - 10
of 1 688
pro vyhledávání: '"Y Van Der Graaf"'
Autor:
Shahnam Sharif, Y. Van der Graaf, M. J. Cramer, L. J. Kapelle, G. J. de Borst, Frank L. J. Visseren, Jan Westerink, the SMART study group
Publikováno v:
Cardiovascular Diabetology, Vol 20, Iss 1, Pp 1-8 (2021)
Abstract Background Type 2 diabetes is a condition associated with a state of low-grade inflammation caused by adipose tissue dysfunction and insulin resistance. High sensitive-CRP (hs-CRP) is a marker for systemic low-grade inflammation and higher p
Externí odkaz:
https://doaj.org/article/d111bce3c9f04bb99a2b41879fa13076
Autor:
D. E. Grobbee, F. L. J. Visseren, R. van Petersen, Jan Westerink, Y. van der Graaf, Maarten J. Cramer, B. G. F. Dinther, T. Leiner, H. M. Nathoe, Frank L.J. Visseren, Shahnam Sharif, A. Algra, G. E. H. M. Rutten, L. J. Kapelle, G.J. de Borst, L.J. Kappelle
Publikováno v:
Cardiovascular Diabetology, Vol 20, Iss 1, Pp 1-8 (2021)
Cardiovascular Diabetology
Cardiovascular Diabetology
Background Type 2 diabetes is a condition associated with a state of low-grade inflammation caused by adipose tissue dysfunction and insulin resistance. High sensitive-CRP (hs-CRP) is a marker for systemic low-grade inflammation and higher plasma lev
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a614a49196c7e936322f35adc661871a
https://doaj.org/article/d111bce3c9f04bb99a2b41879fa13076
https://doaj.org/article/d111bce3c9f04bb99a2b41879fa13076
Autor:
Frank L.J. Visseren, Ynte M. Ruigrok, Jan Westerink, G.J. de Borst, Joseph M. Massaro, Folkert W. Asselbergs, J A N Dorresteijn, Y. van der Graaf, C.C. Van 'T Klooster, Deepak L. Bhatt, Phillippe Gabriel Steg
Publikováno v:
International journal of cardiology, 325, 140-148. Elsevier Ireland Ltd
Background Existing cardiovascular risk scores for patients with established cardiovascular disease (CVD) estimate residual risk of recurrent major cardiovascular events (MACE). The aim of the current study is to develop and externally validate a pre
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5a403fd218e3bb67de9fd548f9c329ad
https://doi.org/10.1016/j.ijcard.2020.09.053
https://doi.org/10.1016/j.ijcard.2020.09.053
Autor:
Nancy R. Cook, Folkert W. Asselbergs, Joachim G.J.V. Aerts, Paul M. Ridker, Frank L.J. Visseren, Y. van der Graaf, C.C. Van 'T Klooster, Jan Westerink
Publikováno v:
European Heart Journal. 41
Background As treatment for cardiovascular disease (CVD) has improved substantially over the last decades, more patients survive acute CVD manifestations and are at risk for developing cancer as well as recurrent CVD. Due to similar risk factors, inc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bd52d8408b96f45381ebe94b0ce9fc97
https://doi.org/10.1093/ehjci/ehaa946.2815
https://doi.org/10.1093/ehjci/ehaa946.2815
Autor:
Paul M. Ridker, Folkert W. Asselbergs, Jesper Hjortnaes, Ivonne Sluijs, M. L. Bots, Jan Westerink, L. J. Kappelle, Frank L.J. Visseren, C.C. Van 'T Klooster, Y. van der Graaf
Publikováno v:
Atherosclerosis. 301
Background and aims Pharmacological lowering of inflammation has proven effective in reducing recurrent cardiovascular event rates. Aim of the current study is to evaluate lifestyle changes (smoking cessation, weight loss, physical activity level inc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0d9d4c7b0bfc1fe38b953026da11d76e
https://pubmed.ncbi.nlm.nih.gov/32527466
https://pubmed.ncbi.nlm.nih.gov/32527466
Publikováno v:
Artery Research, Vol 1, Iss 2 (2007)
Externí odkaz:
https://doaj.org/article/86760759c9d24c50b99a1a9a90de4126
Publikováno v:
European Heart Journal. 40
Background The Action for Health in Diabetes trial (Look AHEAD) randomized overweight and obese patients with type 2 diabetes to either an intensive lifestyle intervention (ILI) or diabetes support and education (DSE). The trial was stopped early for
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bf2b77ad8e73ebf96faafa6e84a70558
https://doi.org/10.1093/eurheartj/ehz746.0168
https://doi.org/10.1093/eurheartj/ehz746.0168
Autor:
T I De Vries, J W Eikelboom, J Bosch, J Westerink, J A N Dorresteijn, M Alings, L Dyal, S D Berkowitz, Y Van Der Graaf, K A A Fox, F L J Visseren
Publikováno v:
European Heart Journal. 40
Background The Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) trial has demonstrated that adding low-dose rivaroxaban to aspirin in patients with stable atherosclerotic disease on average reduces recurrence of cardiovas
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4caa95c46c1484198f4ac5666e5846fb
https://doi.org/10.1093/eurheartj/ehz748.0099
https://doi.org/10.1093/eurheartj/ehz748.0099
Autor:
C C Van 'T Klooster, P M Ridker, J Hjortnaes, Y Van Der Graaf, F W Asselbergs, J Westerink, J G J V Aerts, F L J Visseren
Publikováno v:
European Heart Journal. 40
Background Chronic systemic low-grade inflammation, measured by elevated plasma concentrations of high sensitive C-reactive Protein (CRP), is a risk factor for cardiovascular disease (CVD). There is evidence that systemic low-grade inflammation is al
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9810f21d4fee0a70b1c0226fb8dcc1e8
https://doi.org/10.1093/eurheartj/ehz748.0088
https://doi.org/10.1093/eurheartj/ehz748.0088
Autor:
Yvo M. Smulders, O C Damman, Y. van der Graaf, Frank L.J. Visseren, N E M Jaspers, J A N Dorresteijn
Publikováno v:
European Heart Journal. 40
Background Several online tools express an individual's therapy-benefit for various cardiovascular disease (CVD) prevention strategies. The benefit can be expressed in multiple formats, such as absolute 10-year CVD risk reduction or gain in CVD-free
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e4352c259fb5ed646dcf2225c4305993
https://doi.org/10.1093/eurheartj/ehz747.0253
https://doi.org/10.1093/eurheartj/ehz747.0253